BioNeutra Global (TSXV:BGA) ROCE % : 11,122.12% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is BioNeutra Global ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioNeutra Global's annualized ROCE % for the quarter that ended in Dec. 2023 was 11,122.12%.

BioNeutra Global ROCE % Historical Data

The historical data trend for BioNeutra Global's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNeutra Global ROCE % Chart

BioNeutra Global Annual Data

Trend

Feb14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-66.02

-35.97

-39.43

-60.44

-73.15

BioNeutra Global Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-105.46	-135.07	-463.20	-	11,122.12

BioNeutra Global ROCE % Calculation

BioNeutra Global's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.41	/	( ( (19.782 - 16.91)	+	(15.767 - 14.784) )	/ 2 )
	=	-1.41	/	( (2.872	+	0.983)	/ 2 )
	=	-1.41	/	1.9275
	=	-73.15 %

BioNeutra Global's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	6.284	/	( ( (15.785 - 16.655)	+	(15.767 - 14.784) )	/ 2 )
	=	6.284	/	( ( -0.87	+	0.983 )	/ 2 )
	=	6.284	/	0.056499999999999
	=	11,122.12 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BioNeutra Global (TSXV:BGA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioNeutra Global ROCE % Related Terms

Thank you for viewing the detailed overview of BioNeutra Global's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNeutra Global (TSXV:BGA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioNeutra Global Corp (TSXV:BGA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BGACF:USA

Address

9608 - 25 Avenue NW, Edmonton, AB, CAN, T6N 1J4

Website

http://www.bioneutra.ca

BioNeutra Global Corp is engaged in the research, development, production, and commercialization of food ingredients for neutraceutical, functional and mainstream foods, focusing on oligosaccharides. Its product portfolio provides ingredients for various food systems, that contribute to human nutrition and wellness in functional and healthy foods. Its prime product, VitaFiber IMO, is offered in both powder and syrup form. The company operates in Canada while generating sales revenue from various countries internationally. It has a single industry segment, manufacturing and trading of products. The majority of the revenue is derived from the United States.

BioNeutra Global (TSXV:BGA) Headlines

No Headlines